HK memory names fell in sympathy with WDC stateside
AI model names bucked the tape: MiniMax +17%, Zhipu +4%
Coal and TCM names firmed as money rotated defensive
Today's Watchlist
SNDK grew revenue 372% at an 84.6% gross margin, yet fell 6.81%
Falling NAND spot pricing is the memory chain's core variable today
SNDK's multiple compressed to 17.3x post-earnings, a valuation reset
Beats punished again: guidance now outweighs the quarter itself
INSM +33.9% on TPIP data and peak sales guidance above $14B
SPCX +6.14% as the lockup supply shock failed to materialize
Deep Dives (6 names)
Neutral
6
WDCWestern Digital Corporation · Computer Peripherals
MomentumSocial Buzz
New today“Beat on both revenue and earnings and still lost 13% in a day — felled not by its own results but by its own words on NAND spot pricing. High inventory ahead of a separation is the last thing you want mentioned right now”
Technicals — It closed at $451.52, down 13.03%, with relative volume of 2.02x confirming panic selling. Price sliced 19.8% below the 50-day ($563.12) while holding 32.9% above the 200-day ($339.64). RSI(14) at 40.1 and RSI(7) at 33.6 have weakened without reaching oversold, meaning there is technically room to fall further. The stock is down 11.8% on the week and 15.2% on the month, with an ATR of $55.75 implying a 12.3% daily range, and sits 43.6% below its $799.87 high. There is no clear technical support beneath; the nearest structural level is the $400 round number.
Fundamentals — The quarter delivered EPS of $3.56 on $3.75B of revenue, beating on both lines, with trailing net income up 371.3% at a multiple of just 18.7x. But trailing revenue is down 2.7%, which exposes the problem: the earnings surge came from pricing rather than volume. Three pressures compound — a sudden drop in NAND spot pricing threatening gross margin, intensifying competition, and high inventory ahead of the planned business separation. The company beat and cut guidance in the same breath, the combination markets tolerate least.
News — Western Digital's 13.03% plunge on 8/6 was the epicenter of the day's memory selloff. The company beat on both sales and earnings yet cut guidance, and the reason it gave was industry-wide: a sudden downturn in NAND spot pricing, compounded by intensifying competition and elevated inventory ahead of the business separation, all threatening gross margin. The damage far exceeded the company itself — it dragged SanDisk (-6.81%) and Micron (-1.31%) down the same day, even though SanDisk had just posted 372% revenue growth at an 84.6% gross margin. Today's pricing logic across the entire memory chain was rewritten by that single line from Western Digital.
Short-term · 1–3 weeks
NeutralSidelines
No direction here. WDC must be separated from SNDK and MU: SanDisk and Micron were dragged down by someone else's news, while Western Digital supplied its own reason to cut. Trailing revenue down 2.7% shows its earnings surge came entirely from pricing — precisely what is now in question — making it the most levered of the three to this cycle. RSI(14) at 40.1 is not yet oversold, so there is technical room below, and the 48.7% consensus upside is stale data from before the cut. High inventory ahead of the separation is a variable with a timeline but no price. Wait for evidence NAND spot has stabilized.
Entry Sidelines; wait for evidence NAND spot pricing has stabilizedStop —Target —
Long-term · months+
Neutral
A 18.7x multiple against 371.3% earnings growth looks cheap, but trailing revenue down 2.7% shows the earnings rest entirely on price. The separation may unlock value, but only after the inventory and pricing variables settle.
Falling NAND spot pricing hits gross margin directly, as the company itself confirmed
High inventory ahead of the separation becomes a liability in a falling-price cycle
WSB · Mentions fell from 165 to 71: down 13% and nobody showed up to buy the dip. Retail read it correctly — when a company itself says inventory is high and prices are falling, that isn't a mispricingOriginal ↗
Institutional Views
华尔街共识 · 30 analysts average a $671.57 target, about 48.7% above spot, at a 1.35 buy rating — but these predate the guidance cut and a reset is unavoidable
0.00%07-14“The first time since going public it missed its own guidance midpoints, with EPS a single cent from perfect. But the market never wanted perfect, it wanted acceleration. Nine words — model improvement slower than normal in core gaming — cost a fifth of the company”
Score6/10RSI(14) 28.9RSI(7) 21.3Q2 revenue $1.92B vs $1.94B est.vs 52w high -55.0%Consensus upside +70.3%
Technicals — It closed at $335.67, down 19.66%, within 1.0% of its 52-week low at $332.19, on relative volume of 2.11x confirming panic selling. Price sliced through the 50-day ($482.93) and 200-day ($516.19), leaving a thoroughly bearish stack. RSI(14) at 28.9 and RSI(7) at 21.3 are both deeply oversold. The stock is down 14.6% on the week, 37.9% on the month and 55.0% from its $745.61 high, with an ATR of $29.59 implying an 8.8% daily range. The $332.19 low sits 1.0% below as the only technical reference — but a stock making new lows has no support to speak of.
Fundamentals — Q2 adjusted EPS of $3.76 versus $3.75 expected was nearly perfect, while revenue of $1.92B grew 53% but fell short of the $1.94B estimate. Q3 revenue guidance of $2.06–2.09B carries a $2.07B midpoint just under the $2.08B consensus. The trailing figures are genuinely attractive: 20.0% revenue growth, 104.7% EPS growth, an 87.5% gross margin and a multiple of only 29.6x. The problem isn't the numbers but management's remarks on the call: the core gaming segment underperformed because model improvement ran slower than normal — and model improvement is what the company itself identifies as its key growth driver. Piper Sandler noted this was the first time since the IPO that it missed its own revenue and adjusted EBITDA guidance midpoints.
News — AppLovin plunged 19.66% on 8/6, among the largest declines by any mid-to-large-cap tech name that day. The print itself wasn't bad: EPS of $3.76 edged past the $3.75 estimate on 53% revenue growth. The damage came from two places — revenue of $1.92B missed the $1.94B estimate, and management conceded on the call that the core gaming segment underperformed because the model improvement driving growth ran slower than normal. Piper Sandler flagged that this was the first time since the IPO that AppLovin missed both its own revenue and adjusted EBITDA guidance midpoints. For a company whose valuation premium was built on always beating, breaking that streak is itself the event.
Short-term · 1–3 weeks
NeutralSidelines
No direction. A 29.6x multiple with an 87.5% gross margin, 104.7% EPS growth and 70.3% consensus upside makes this the day's most tempting apparent mispricing — but all three numbers are compromised. That upside rests on pre-earnings targets and cuts are only a matter of time; the deeply oversold reading came on a day the stock approached its 52-week low, which marks the start of a trend rather than its end; and management's admission that model improvement is running slower than normal points to the growth engine itself decelerating, not a one-off disturbance. Reassess once targets reset and the $332.19 low survives a test.
Entry Sidelines; wait for targets to reset and for $332.19 to holdStop —Target —
Long-term · months+
Neutral
An 87.5% gross margin and 104.7% EPS growth show the model's leverage remains powerful, and 29.6x isn't demanding for a growth name. But growth depends entirely on continuous improvement of the ad model, and management has just conceded that engine is slowing.
Slowing model improvement strikes at the growth engine itself, not a one-off
The first miss of its own guidance midpoints since the IPO breaks the premise of its valuation premium
Consensus targets don't yet reflect this print, leaving large downgrade risk
Community Voices
StockTwits · Absent from the trending board: a 20% drop and no crowd. This was never a retail name — these are institutions recalculating what a company that always beats is worth once it doesn'tOriginal ↗
Institutional Views
华尔街共识 · 36 analysts average a $571.72 target, a striking 70.3% above spot, at a 1.21 rating near strong buy — but these predate the print and bulk cuts are near-certain
Piper Sandler · Noted this was the company's first miss of its own revenue and adjusted EBITDA guidance midpoints since going publicSource ↗
New today“Beat, raised full-year guidance, still growing large enterprise accounts — and earned its largest down candle ever. At 611x, good enough is the verdict, and one soft sequential quarter repays three years of borrowed multiple”
Score6/10RSI(14) 39.0Q2 results EPS $0.65 vs $0.58; revenue $1.12B vs $1.08BFCF margin 29% → 25%P/E TTM 611.91-day drop -19.03% (record)
Technicals — It closed at $229.29, down 19.03%, the largest single-day decline in company history — surpassing the roughly 17.8% drop of March 2020 — on relative volume of 3.40x. Price sliced through the 50-day ($248.83) while holding 35.3% above the 200-day ($169.51). RSI(14) at 39.0 and RSI(7) at 29.2 have turned weak, but with RSI(14) still above 30 there is technical room below. The stock fell 13.1% on the week and 10.8% on the month, with an ATR of $16.34 implying a 7.1% daily range, and sits 21.7% under its $292.72 high. The nearest structural support is the $200 round number, then the 200-day at $169.51.
Fundamentals — Q2 EPS of $0.65 beat the $0.58 estimate and revenue of $1.12B beat $1.08B, while the company raised both full-year revenue and earnings guidance and kept growing high-value enterprise customers. Q3 guidance of $0.63–0.65 EPS on $1.135–1.145B revenue tops consensus of $0.61 and roughly $1.11B. This was a comprehensive beat-and-raise. Yet the market fixed on two things: free cash flow margin compressing from 29% to 25%, and a flattening sequential growth slope. A 611.9x trailing multiple against 29.5% revenue growth means any deceleration gets repaid in market capitalization.
News — Datadog fell 19.03% on 8/6, its largest single-day decline on record, despite a comprehensive beat and a raised full-year outlook, having traded down as much as 20% premarket. Three explanations circulated: free cash flow margin compressing from 29% to 25%; modest sequential growth guidance read as a possible slowdown in core observability demand; and reports that a leading AI customer flagged a weaker second-half outlook. Fundamentally this was a sell-the-fact reaction — a 611.9x valuation requires not a beat but an accelerating beat. Several analysts argued afterward that the selloff created a buying opportunity.
Short-term · 1–3 weeks
NeutralSidelines
No direction. The print was objectively good — a beat, a raise, growing enterprise accounts — and the selloff is a valuation problem rather than an operating one. That is precisely why I won't catch it today: repricing a 611.9x multiple doesn't finish in a session, RSI(14) at 39.0 hasn't reached oversold so there is technical room below, and the free cash flow compression from 29% to 25% needs another quarter to confirm or refute. Wait for RSI to genuinely reach oversold and for the $200 round number to produce a clear reaction; only then is the risk/reward measurable.
Entry Sidelines; wait for RSI to reach oversold and for $200 to produce a reactionStop —Target —
Long-term · months+
Neutral
Revenue growth of 29.5%, a 79.9% gross margin and steadily growing high-value enterprise accounts show the observability demand base is solid. But a 611.9x trailing multiple means the gap between valuation and fundamentals takes years of growth to close.
Free cash flow margin fell from 29% to 25%, a deteriorating return on spending
A leading AI customer reportedly flagged a weaker second-half outlook
At 611.9x, any deceleration is amplified into a crash
Community Voices
StockTwits · Absent from the trending board on a record decline. That means institutions repricing a 611x asset, not a sentiment tradeOriginal ↗
Institutional Views
华尔街共识 · 50 analysts average a $282.80 target, roughly 23.3% above spot, at a 1.23 rating near strong buy — though these predate the print
New today“An 8% EPS beat and a revenue beat, and it still lost a fifth over two or three thousand missing customers. A growth multiple never buys past profit, it buys the next cohort — and this cohort didn't show up”
Score5/10RSI(14) 44.3Q2 results EPS $3.26 vs $3.02; revenue $911.7MNet new customers 7,000 vs 9,000–10,000 targetvs 52w high -61.5%1-day drop -19.1% (record)
Technicals — It closed at $202.43, down 19.10%, the largest single-day decline in company history, on relative volume of 4.58x. Price broke the 50-day ($207.55) and sits 28.2% below the 200-day ($282.08) in a thoroughly bearish stack. RSI(14) at 44.3 and RSI(7) at 35.2 have weakened without reaching oversold. The stock fell 14.2% on the week yet remains up 1.2% on the month, indicating it had been basing at low levels. ATR of $20.09 implies a 9.9% daily range. It now sits 61.5% below the $525.51 high and only 19.3% above the $169.63 low.
Fundamentals — Q2 adjusted EPS of $3.26 beat the $3.02 estimate by 7.9% and revenue of $911.7M grew 19.8%, also topping the roughly $898M consensus. Trailing revenue growth is 21.1% on an 83.2% gross margin at 71.7x earnings. The damage sits in three forward data points: full-year revenue guidance was cut; Q3 revenue guidance of roughly $924.5M came in about 1.8% below consensus and implies deceleration to around 14% growth; and net new customers totaled just 7,000 for the quarter, reaching 306,446, well below the company's internal 9,000–10,000 target. Investor skepticism about the pace of AI monetization overwhelmed the quarter's beat.
News — HubSpot fell 19.10% on 8/6, its largest single-day decline on record, followed by multiple downgrades and target cuts. The print itself beat — EPS of $3.26 versus $3.02 and revenue of $911.7M versus roughly $898M — but three forward blows compounded: full-year revenue guidance was cut, Q3 guidance landed about 1.8% below consensus implying deceleration to roughly 14%, and net new customers of 7,000 fell far short of the internal 9,000–10,000 goal. Doubts about the pace of HubSpot's AI monetization were confirmed by this report. Some analysts framed it as a transition from growth stock to value stock — a transition that typically comes with a systematic reset lower in the valuation anchor.
Short-term · 1–3 weeks
NeutralSidelines
No direction. The distinction from DDOG must be stated: DDOG beat and was punished by its multiple, whereas HubSpot cut its own full-year outlook and badly missed its internal customer-add target — that is operating deceleration, not merely a valuation issue. Implied growth falling from 19.8% to roughly 14% is a genuine change in slope. RSI(14) at 44.3 isn't even near oversold, so the selling may be unfinished, and with several firms downgrading, the $240.18 target will keep drifting lower. Until there is evidence growth has stabilized, an 18.6% paper upside isn't worth the bet.
Entry Sidelines; wait for downgrades to finish and for evidence growth has stabilizedStop —Target —
Long-term · months+
Neutral
An 83.2% gross margin and a base above 300,000 customers show the product moat holds, and 71.7x would not be expensive if growth returned above 20%. But implied growth of 14% and customer adds below its own target suggest penetration of the SMB CRM market is topping out.
Net customer adds far below the internal target signal a decelerating growth engine
The market broadly doubts its AI monetization pace, with no verifiable data yet
Multiple firms are cutting ratings and targets; the reset is unfinished
Community Voices
StockTwits · Absent from the trending board on a record drop. SaaS valuation resets happen quietly — by the time retail notices, the anchor has already movedOriginal ↗
Institutional Views
华尔街共识 · 37 analysts average a $240.18 target, about 18.6% above spot, at a 1.55 rating leaning neutral — with several firms already downgrading and cutting targets after the close
New today“The first report as a standalone company came with a $300M guidance cut. Precision castings are scarce, every one goes to Boeing and Airbus OEM lines, and the high-margin aftermarket waits. This isn't a demand problem — it's being last in the queue”
Score5/10RSI(14) 32.3RSI(7) 20.2Q2 EPS $1.87 vs $2.12 est. (-32% YoY)FY guidance cut $300MOrganic growth guide 7–9% → 4–5%
Technicals — It closed at $156.47, down 23.16%, printing a fresh 52-week low of $150.03 intraday on relative volume of 7.54x — extreme panic selling. The name lacks 50-day and 200-day references given its short standalone history, leaving the $150.03–$297.50 52-week range as the only anchor, with price just 4.3% above the low. RSI(14) at 32.3 and RSI(7) at 20.2 are both deeply oversold. It fell 23.8% on the week and 34.2% on the month, with an ATR of $17.33 implying an 11.1% daily range. Without a moving-average structure, support can only be inferred from volume shelves, far less reliably than for a seasoned name.
Fundamentals — In its first quarter as a standalone company, revenue of $4.52B grew 5% while adjusted EPS collapsed 32% to $1.87, far below the $2.12 consensus, with roughly $100M attributable to separation costs and inventory obsolescence. Full-year guidance was cut by $300M and organic sales growth guidance slashed from 7–9% to 4–5%. The cause is a physical supply constraint: a precision casting shortage means scarce parts are routed first to Boeing and Airbus OEM lines, squeezing the higher-margin aftermarket business. No P/E or gross margin data is available for cross-checking.
News — Honeywell Aerospace fell as much as 24% intraday on 8/6, touching a post-listing low of $150.03 before closing down 23.16%. This was its first report as a standalone company and a textbook failed debut. The company cut full-year 2026 guidance by $300M, explaining that a precision casting shortage forces scarce parts toward Boeing and Airbus OEM lines rather than the higher-margin aftermarket. Adjusted EPS fell 32% year over year to $1.87, including roughly $100M of separation costs and inventory obsolescence charges, and organic sales growth guidance was cut from 7–9% to 4–5%.
Short-term · 1–3 weeks
NeutralSidelines
No direction. RSI(7) at 20.2 and 53.7% consensus upside look tempting, but three obstacles stand in the way. There is no 50-day or 200-day, so even a technical stop cannot be set reliably. That 53.7% comes from only 16 analysts using pre-cut targets. And the casting shortage is a physical supply constraint with no published resolution timeline — unlike a one-off write-down it cannot be modeled, and it will keep squeezing aftermarket revenue. Day one of a new listing low offers no support. Wait for evidence the constraint is easing.
Entry Sidelines; wait for evidence the casting supply constraint is easingStop —Target —
Long-term · months+
Avoid
Aftermarket should be aerospace's highest-quality cash flow stream, yet the casting shortage prevents the company from allocating parts to it. Until the supply constraint clears, the valuation flexibility promised by the spin-off cannot be realized.
The precision casting shortage has no published resolution timeline
Organic growth guidance was nearly halved, from 7–9% to 4–5%
Without moving averages or valuation benchmarks, risk cannot be measured conventionally
Community Voices
StockTwits · Absent from the trending board despite a 23% drop to new lows. A freshly spun-off name has no shareholder base, and therefore nobody to catch the knifeOriginal ↗
Institutional Views
华尔街共识 · 16 analysts average a $240.42 target, a striking 53.7% above spot, at a 1.69 rating leaning neutral — thin coverage and pre-cut data, so of limited use
Neutral
6
SPCXSpace Exploration Technologies Corp · Space & Communications
MomentumSocial BuzzWatchlist
+1.83%07-02“Two days ago everyone was waiting for the lockup to crush it; on the day itself it rose 6.14%. What defeats a supply shock is never the selling — it's everyone having already crowded onto the same side of the boat”
Score6/10RSI(14) 42.51-day gain +6.14%Q2 revenue $7.81B / +92%Q2 capex $184亿 / $18.4BLockup expiry 8/6, now passed
Technicals — It closed at $114.92, up 6.14%, on relative volume of 2.93x — a high-volume advance on lockup day, the opposite of what the market broadly expected. The name still lacks 50-day and 200-day references, leaving the $104.83–$225.64 52-week range as the only anchor, with price 9.6% above the low and 49.1% below the high. RSI(14) at 42.5 and RSI(7) at 46.2 are both neutral. The week is down just 0.2% while the month is down 27.7%. ATR of $11.10 implies a 9.7% daily range. Technical analysis here remains constrained by the absence of moving-average structure.
Fundamentals — Q2 revenue of $7.81B grew 92% and beat estimates, but quarterly capital expenditure of roughly $18.4B ran at 2.4x revenue. The company is now a three-segment enterprise spanning space, connectivity and AI following the February 2026 integration of xAI and X, at a market capitalization near $1.51T. There is still no P/E or gross margin available for cross-checking, making it the least financially transparent name in today's deep dives. The $227.09 consensus target implies 97.6% upside, the highest on the board — but that figure rests on an extremely thin base of verifiable financials.
News — August 6 was SpaceX's first major post-listing lockup expiration — the foreseeable supply shock I named explicitly in the two prior briefs. The outcome inverted the expectation: the stock rose 6.14% on relative volume of 2.93x. The maiden report after the close on 8/4 had knocked it as much as 8.8% postmarket on $18.4B of quarterly capex, but that damage was largely repaired within two sessions. Two things follow: the market had priced lockup selling fully, arguably excessively, in advance; and the 92% revenue growth narrative still finds buyers. The question of payback on that capex isn't resolved — merely deferred.
Short-term · 1–3 weeks
NeutralSidelines
Staying sidelined, but the part I got wrong needs stating plainly: in the two prior briefs I flagged the 8/6 lockup as a foreseeable supply shock, and the actual outcome was a 6.14% advance on heavy volume. That call was directionally wrong, because the market had already priced the selling in advance. The core reason for taking no direction, however, still holds unchanged: without a 50-day or 200-day, a stop cannot be set reliably; quarterly capex at 2.4x revenue leaves the payback period entirely unclear; and there is no P/E or gross margin to cross-check. A 97.6% consensus upside cannot be supported by verifiable financials. Wait for the moving-average structure to form.
Entry Sidelines; wait until a 50-day forms and a technical framework becomes possibleStop —Target —
Long-term · months+
Neutral
Revenue growth of 92% and a unique three-segment footprint across space, connectivity and AI make for an unmatched asset base, and the strength on lockup day shows the market will pay a premium for that narrative. But with quarterly capex at $18.4B, the valuation rests on story until free cash flow turns positive.
The payback period on $18.4B of quarterly capex is entirely unclear
Without P/E or gross margin data, the valuation cannot be cross-checked
Lockup selling didn't hit on day one, but the added float is a persistent supply
Signal BacktestCumulative +1.83%price itself -27.05%1/1 closed trades wonprofitable since 07-04
07-02Long$157.54 → closed $160.4207-07+1.83%
Community Voices
WSB · At 398 mentions for third place, easing from 450 but still near the top with 1,508 upvotes. Retail didn't run on lockup day — it stayed to watch, an unusual composure for the occasionOriginal ↗
Institutional Views
华尔街共识 · 38 analysts average a $227.09 target, a striking 97.6% above spot, at a 1.37 buy rating — the widest upside on the board, backed by the least verifiable financial data
Down 1.29% through the structural support near the 50-day at $99.00 with RSI(7) weakening to 41.2, and it sits in the same aerospace supply chain as HONA and BA where the casting-shortage spillover isn't priced. Closing the position until that variable clears.
Down 7.01% in a sharp give-back; RSI is 57.0 but a 77.4x multiple against EPS down 17.0% and revenue down 2.0% cannot support the valuation. Closing the position.
Up 0.77% but still 36% below the 50-day at HK$184.85 after a 27.2% month, with RSI weak at 41.4. The fiber demand narrative diverges sharply from the price and only eight analysts cover it. Closing the position pending trend confirmation.
Up 0.69% but still down 51.7% on the month and 41% below the 50-day at HK$60.02, with RSI weak at 37.6. The laminate cycle hasn't bottomed and yesterday's entry rationale is too thin. Closing the position.
Up 1.50% but still below the 50-day at $514.33 with RSI neutral at 47.8, as WSB mentions collapsed from 1,137 to 71, down 94%. Post-earnings attention drained without the position improving; staying sidelined.
Up 2.54% against the tape to $499.86, but RSI at 78.1 and RSI(7) at 86.1 are deeply overbought with consensus upside of just 12.3%. Closed out yesterday; staying sidelined pending a pullback.
Down 2.91% off the $305.00 high with RSI easing to neutral at 58.7; the $267.69 consensus target still sits 5.9% below spot and the valuation remains undigested after the 8/6 print. Staying sidelined.
Down 13.29% on doubts over AI capex returns and pressure across neoclouds, with RSI neutral at 46.2 yet still 15% below the 50-day at $223.94; volatility ahead of the 8/12 print is extreme. Sidelines.
Down 13.30% through both the 50-day at $359.53 and 200-day at $328.71 with RSI weakening to 44.1; AI server manufacturing took the brunt of capex doubts and the 52.0% consensus upside awaits revision. Sidelines.
Up 15.05% on Q2 revenue of $546M versus $515M expected and adjusted EPS of $0.28 against a $0.09 loss estimate, with Q3 guidance also above consensus — but RSI at 78.7 is deeply overbought and consensus targets sit 7.6% below spot. Sidelines.
Up 33.86% on positive 12-month TPIP extension data, BRINSUPRI revenue of $309.2M up 49% sequentially, and peak sales guidance above $14B — but RSI(7) at 87.1 is extremely overbought and chasing has inverted risk/reward. Sidelines.
Up 2.89% against the tape with RSI overbought at 69.8, above the 50-day at $178.48 and 200-day at $189.80 — but 112x against 6.0% EPS growth leaves the valuation unsupported. Sidelines.
Up 7.31% into fresh 52-week-high territory with RSI overbought at 73.7 on 2.1x volume — but the $1,074.23 consensus target sits just 0.4% above spot, leaving the breakout no valuation room. Sidelines.
Down 4.81% on 3.09x volume with RSI neutral at 51.2 but price below the 200-day at $1,888.79 and 28% off its high; no clear catalyst in Latin American e-commerce today. Sidelines.
Down 6.80% on 5.18x volume with WSB mentions exploding from 1 to 73; at 19.9x it looks cheap, but it sits 69% below its high and under all three moving averages with the adtech reset unfinished. Sidelines.
Up 10.11% and 22.9% for the week with RSI at 59.4 reclaiming the 50-day at $6.87, yet still 23% below the 200-day at $9.25 and 68% off its high, with no earnings anchor in voice AI. Sidelines.
Down 3.38% though the week is still up 49.0%, with RSI neutral at 52.8; the optics theme cooled amid AI capex doubts and price remains below the 50-day at $139.11. Sidelines.
Up 43.09% to a $6.39 52-week high on 5.65x volume after a 46.1% month with RSI at 69.8; cell therapy commercialization isn't yet profitable and the move has no valuation anchor. Sidelines.
Up 29.49% on 7.13x volume as WSB mentions exploded a hundredfold from 14 to 1,396, taking the top spot site-wide — yet price is still 36% below the 50-day at $3.18 and 75% off its high. Pure sentiment; sidelines.
Down 4.25% with RSI(14) at 21.1 and RSI(7) at 9.2 — the most extreme oversold readings on the board — after weekly and monthly declines of 24.6% and 24.4%, below every moving average. The decline hasn't halted; sidelines.
Down 0.41% with RSI(7) extremely oversold at 19.7 after declines of 27.1% for the week and 37.2% for the month, 75% below its high. The downtrend is intact and catching this is high-risk; sidelines.
Down 0.37% with RSI(7) deeply oversold at 15.6, below every moving average and just 6.8% above its 52-week low; utilities keep bleeding as yields rise. Sidelines.
Down 1.60% with RSI(7) extremely oversold at 13.7 after a 14.4% week, below the 50-day at $74.10 and 200-day at $67.33; the risk premium on California utilities isn't fully priced. Sidelines.
Down 0.46% with RSI(7) deeply oversold at 16.4, below the 50-day at $55.27 while hugging the 200-day at $51.80; the defensive appeal of pipeline assets weakens as yields rise. Sidelines.
Down 0.66% with RSI(7) deeply oversold at 15.7, below every moving average and just 1.1% above its 52-week low, as utilities bleed systematically. Sidelines.
Down 0.97% with RSI(7) oversold at 20.8, below every moving average after a 10.1% month, part of the same bleeding utilities cohort as SRE, EIX and PEG. Sidelines.
Down 1.97% with RSI at 24.0 among the lowest on the board, just 1.3% above its 52-week low and below every moving average, as defensives are systematically abandoned. Sidelines.
Down 2.49% with RSI oversold at 31.7 after a 23.0% month, just 5.9% above its 52-week low; HVAC demand tracks a soft residential market with no inflection. Sidelines.
Down 3.10% with RSI(7) deeply oversold at 16.8 after a 19.1% week, closing on the $92.28 low; auction-platform demand is softening with no stabilization signal. Sidelines.
Down another 2.77% with RSI oversold at 28.7 after a 17.7% week, below every moving average; two straight down sessions with no sign of a bottom. Sidelines.
Down 3.22% with RSI(7) deeply oversold at 14.7, slipping between the 50-day at $122.92 and 200-day at $109.11; REITs are pressured as yields rise. Sidelines.
Up 22.62% to a $128.01 52-week high on 4.41x volume with RSI(7) extremely overbought at 87.3 — but the $97.50 consensus target sits 21.8% below spot, leaving no room to chase. Sidelines.
Up 12.55% toward the $127.99 high with RSI overbought at 74.0 on 2.66x volume; at 20.3x against 20.1% EPS growth the fundamentals are sound, but chasing on breakout day isn't rational. Sidelines.
Up 17.32% toward the $24.58 high on 3.09x volume with RSI overbought at 70.5 after a 20.4% month; the background-screening breakout lacks proof of durability. Sidelines.
Up 6.45% toward the $110.08 high with RSI at 68.4 on 1.92x volume; food distribution's defensive profile found favor on a turbulent day, but valuation room is lacking. Sidelines.
Down 0.16% near the $213.26 high with RSI at 64.9 after an 11.7% month; restaurant defensiveness found favor but there was no catalyst today. Sidelines.
Down 50.48% — halved on 14.79x volume — with RSI(7) extremely oversold at 12.7 after declines of 48.0% for the week and 54.7% for the month. Day one of a collapse offers no support; sidelines.
Down 34.22% on 8.55x volume with RSI oversold at 28.3 after declines of 32.7% for the week and 44.9% for the month; vocational-education demand collapsed with no stabilization. Sidelines.
Down 18.55% on 6.77x volume with RSI(7) extremely oversold at 12.6, closing on the $28.90 low; specialty pharma demand is weakening with no sign of a bottom. Sidelines.
Up 22.49% to a $15.62 52-week high on 7.33x volume with RSI(7) extremely overbought at 81.0 after a 16.1% month; a small-cap device name with no verifiable anchor. Sidelines.
Up 37.52% on 13.28x volume and 62.1% for the week with RSI(7) extremely overbought at 83.2; the aerogel demand narrative has no earnings backing. Sidelines.
Up 40.78% on the board's highest relative volume at 17.32x, near the $5.84 high with RSI extremely overbought at 83.0 after a 44.9% week; a sentiment-driven low-priced name. Sidelines.
Down 5.25% with RSI weak at 41.1 after a 16.1% month, still below the 50-day at $12.94 and 200-day at $11.60; bitcoin miners are pressured as risk appetite ebbs. Sidelines.
Down 1.49% though the week is up 21.5%, with RSI neutral at 50.9; the quantum-computing concept remains below the 50-day at $18.68 and 200-day at $21.27, 72% off its high. Sidelines.
Down 2.78% with the software pullback, RSI still firm at 63.0 after a 23.6% month above the 200-day at $108.09 — but with DDOG and HUBS cratering, this isn't the environment to chase. Sidelines.
Down 4.48% on 7.7x volume with RSI weakening to 44.3, 73% below its high and 37% under the 200-day at $32.58; the valuation reset for the physician network isn't finished. Sidelines.
Up 1.88% but with RSI weak at 35.9 after a 16.0% month, still below the 50-day at $25.33 and 200-day at $27.39; both demand and regulation remain uncertain. Sidelines.
Up 8.71% capping an extraordinary 145.0% week, with RSI at 62.4 above the 50-day at $9.81 and 200-day at $7.97; a clinical-stage biotech with no earnings anchor after such a move. Sidelines.
Up 0.12% though the week is up 23.0%, with RSI neutral at 50.5 and price below the 50-day at $10.05 and 200-day at $11.02; the drone concept lacks a revenue anchor. Sidelines.
Down 3.77% with RSI weak at 38.2 after declines of 13.0% for the week and 28.2% for the month, below every moving average; the fast-casual expansion model is under pressure. Sidelines.